Table 2.
Description of artemisinin-containing antimalarial samples analyzed
| Active ingredient | Pharmacy | Drug store (DLDB/ADDO) | General retailer | Total |
|---|---|---|---|---|
| Artemether | ||||
| Artemether monotherapy | 100 | 0 | 0 | 100 |
| Alu | 463 | 36 | 5 | 504 |
| Total | 563 | 36 | 5 | 604 |
| Artemisinin | ||||
| Artemisinin monotherapy | 0 | 0 | 0 | 0 |
| Artemisinin–napthoquine | 121 | 4 | 0 | 125 |
| Artemisinin–piperaquine | 160 | 13 | 0 | 173 |
| Total | 281 | 17 | 0 | 298 |
| Artesunate | ||||
| Artesunate monotherapy | 11 | 0 | 0 | 11 |
| Artesunate–amodiaquine | 32 | 5 | 0 | 37 |
| Artesunate–mefloquine | 295 | 15 | 0 | 310 |
| Artesunate–SP | 159 | 24 | 0 | 183 |
| Total | 497 | 44 | 0 | 541 |
| Dihydroartemisinin | ||||
| Dihydroartemisinin–piperaquine | 266 | 28 | 0 | 294 |
| Total | 266 | 28 | 0 | 294 |
| Total | 1,607 | 125 | 5 | 1,737 |
ADDOs = accredited drug dispensing outlets; Alu = artemether–lumefantrine; DLDBs = duka la dawa baridi; SP = sulfadoxine–pyrimethamine.